» Authors » Terry Sarantou

Terry Sarantou

Explore the profile of Terry Sarantou including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 26
Citations 357
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Kaufman C, Sarantou T, Donovan C, Polat A, Thomas P, Mack B
Ann Surg Oncol . 2024 Apr; 31(7):4541-4542. PMID: 38683306
No abstract available.
2.
Donovan C, Kaufman C, Thomas K, Polat A, Thomas M, Mack B, et al.
Ann Surg Oncol . 2023 Aug; 30(10):6070-6078. PMID: 37528305
Background: The literature lacks well-established benchmarks for expected time between screening mammogram to diagnostic imaging and then to core needle breast biopsy. Methods: Timeliness of diagnostic imaging workup was evaluated...
3.
White Jr R, Wallander M, Leighliter M, Sha W, Palmer P, Sejdic A, et al.
Cancer . 2023 Jun; 129(20):3230-3238. PMID: 37382238
Background: There are few quality metrics and benchmarks specific to surgical oncology. Development of a surgeon-level performance metrics system based on peer comparisons is hypothesized to positively influence surgical decision-making....
4.
Elder E, Livasy C, Donahue E, Neelands B, Patrick A, Needham M, et al.
Ann Surg Oncol . 2022 Aug; 29(13):8060-8069. PMID: 35980548
Background: The residual cancer burden class informs survival outcomes after neoadjuvant chemotherapy. We evaluated the prognostic ability of the RCB for survival outcomes in women with different phenotypic subtypes of...
5.
Teller P, Nguyen T, Tseng J, Allen L, Matsen C, Bellavance E, et al.
Ann Surg Oncol . 2022 Jul; 29(10):6144-6150. PMID: 35854028
The adoption of innovation is essential to the evolution of patient care. Breast surgical oncology advances through incorporating new techniques, devices, and procedures. Historical changes in practice standards from radical...
6.
Pestana C, Livasy C, Donahue E, Neelands B, Tan A, Sarantou T, et al.
Ann Surg Oncol . 2022 Jul; 29(12):7716-7724. PMID: 35810226
Background: The extent of residual disease after neoadjuvant chemotherapy (NAC) can be quantified by the Residual Cancer Burden (RCB), a prognostic tool used to estimate survival outcomes in breast cancer....
7.
Yao K, Attai D, Bleicher R, Kuchta K, Moran M, Boughey J, et al.
Breast Cancer Res Treat . 2021 Jan; 186(3):625-635. PMID: 33517522
Purpose: To examine how treatment delays brought on by the COVID-19 pandemic impacted the physical and emotional well-being of physicians treating these patients. Methods: A cross-sectional survey of physician breast...
8.
Dietz J, Moran M, Isakoff S, Kurtzman S, Willey S, Burstein H, et al.
Breast Cancer Res Treat . 2020 Apr; 181(3):487-497. PMID: 32333293
The COVID-19 pandemic presents clinicians a unique set of challenges in managing breast cancer (BC) patients. As hospital resources and staff become more limited during the COVID-19 pandemic, it becomes...
9.
Yao K, Bleicher R, Moran M, Chang C, Dietz J, Stearns V, et al.
Cancer Med . 2020 Mar; 9(9):3088-3096. PMID: 32159280
Background: Indications and insurance coverage for contralateral prophylactic mastectomy (CPM) and CPM as a quality measure are controversial. Few studies have examined physician opinions on these issues. Methods: A cross-sectional...
10.
Phantana-Angkool A, Voci A, Warren Y, Livasy C, Beasley L, Robinson M, et al.
Ann Surg Oncol . 2019 Jul; 26(12):3874-3882. PMID: 31342378
Introduction: The role of sentinel lymph node biopsy (SLNB) when ductal carcinoma in situ with microinvasion (DCISM) is identified on core biopsy is unclear. Objective: Our aim was to assess...